TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04719689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry cupping
Description: Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
Study: NCT02771743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tandem HDCT/auto-SCT
Study: NCT03588390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to middle strength tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to high strength tablet
Study: NCT02771743

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MIBG
Study: NCT03439774

Intervention type: DEVICE
Intervention: Topcon CT-800
Description: tonometer

Intervention type: DEVICE
Intervention: Topcon TRK-2P
Description: tonometer, pachymeter
Study: NCT01165775

Intervention type: DEVICE
Intervention: Dexcom Seven Plus Continuous Glucose Monitoring System
Description: Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
Study: NCT03577587

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silitidil for 21 days
Description: daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
Study: NCT02652299

Intervention type: BIOLOGICAL
Intervention: Synovial biopsy
Description: Synovial tissue for analysis and biobank.

Intervention type: BIOLOGICAL
Intervention: Synovial biopsy
Description: Synovial tissue for analysis and biobank.

Intervention type: BIOLOGICAL
Intervention: Synovial biopsy
Description: Synovial tissue for analysis and biobank.
Study: NCT01631318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced ultrasound imaging
Description: Ultrasound imaging procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Tracking Device
Description: Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Tracking Device
Description: Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren
Description: Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.
Study: NCT04723784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial Assessment
Description: In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of assistive technology in the daily life of participants
Description: The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of outcome measures
Description: After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
Study: NCT00572299

Intervention type: DRUG
Intervention: alendronate
Description: 70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
Study: NCT00443755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
Study: NCT03588390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to high strength tablet
Study: NCT01937364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
Study: NCT03309800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301
Description: HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HL301(Placebo)
Description: HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
Study: NCT00658320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
Study: NCT02040428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVARREST™ Fibrin Sealant Patch

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Topical hemostat
Study: NCT01393990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2228820
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Study: NCT00793728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
Study: NCT00993616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT02660190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hexaminoavolunate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WL cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WL cystoscopy
Study: NCT00312000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine-irinotecan
Description: 1. st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~2. nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine+irinotecan (1st line)
Description: q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
Study: NCT02702557

Intervention type: OTHER
Group type: OTHER
Intervention: Elastic Band Exercises
Study: NCT04003831

Intervention type: DEVICE
Group type: OTHER
Intervention: Device: P200TxE
Description: The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
Study: NCT02317276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone 0.1%
Description: Topical ointment
Study: NCT02782117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia One
Description: Luminopia One is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.
Study: NCT00389532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
Description: Influenza vaccine
Study: NCT00627718

Intervention type: DEVICE
Group type: OTHER
Intervention: HRT screening for macula edema
Description: HRT screening for macula edema at time of initial diagnosis of macular degeneration
Study: NCT04144296

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Study procedure
Description: * Measurement of the flow rate of supplemental oxygen~* Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~* Taking of an ABG sample (ABG1) from the arterial line~* Taking of capillary blood gas analysis from the earlobe and from the finger tip~* Taking of an a second ABG (ABG2) from the arterial line
Study: NCT04457869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: 3mg/kg every 3 weeks
Study: NCT02035137

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 131I-MIBG

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 131I-MIBG

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 131I-MIBG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Study: NCT03577587

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 21 days
Description: daily ingestion of Placebo preparation over time period of 3 weeks
Study: NCT02035137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Study: NCT02325388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForeSite PT™ system
Description: XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the ForeSite PT™ system) continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts.
Study: NCT02816138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Open-label transdermal nicotine patch
Study: NCT03066050

Intervention type: OTHER
Intervention: MV Repair
Description: Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.

Intervention type: OTHER
Intervention: MV Repair
Description: Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.

Intervention type: OTHER
Intervention: MV Replacement
Description: Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
Study: NCT03053791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation in mesencephalic locomotor region
Description: Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of a Deep brain stimulation system
Description: Implantation of a Medtronic Percept PC Impulse Generator for chronic Stimulation of the selected target.
Study: NCT03066050

Intervention type: OTHER
Intervention: CABG
Description: Participants underwent coronary artery bypass grafting
Study: NCT04133727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of an ageing suit
Description: The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polypharmacy workshop
Description: Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
Study: NCT03249155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AO - plus sonification
Description: patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif_example)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CUE - visual and auditory
Description: patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
Study: NCT00772226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: music pillow
Description: according to randomisation patients will receive with/without music.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pillow without music
Description: According to randomisation patients will receive a pillow with/without music
Study: NCT03083899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Out-patient clinic on demand (patient-initiated)
Description: Free use of any resources in the out-patient clinic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scheduled out-patient clinic
Description: Scheduled use of the out-patient clinic
Study: NCT01951625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (1.25 mg)
Description: 1.25 mg BAY1021189 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (5 mg)
Description: 5 mg BAY1021189 tablets
Study: NCT02406040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
Study: NCT01951625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189) (5 mg)
Description: 5 mg BAY1021189 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01592370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered PO and by IV infusion
Study: NCT03535337

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPS
Description: Assessment of participant's medication adherence and barrier problem solving via phone conversation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPS
Description: Assessment of participant's medication adherence and barrier problem solving via phone conversation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPS
Description: Assessment of participant's medication adherence and barrier problem solving via phone conversation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPS
Description: Assessment of participant's medication adherence and barrier problem solving via phone conversation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS
Description: Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.